Several clinical studies have reported that 20–40% of IBD patients fail to respond to anti-TNF-α induction therapy, whereas nearly 50% of those with an initial response may lose responsiveness to anti-TNF-α maintenance therapy following the induction phase.4,5 Current therapeutic limitations stem from an incomplete understanding of the molecular pathogenesis, leading to frequent treatment failure. This evidence concerns the gene TNF and inflammatory bowel disease.